Last Price$0.41NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/30/22

Today's Change+0.004(0.98%)
Bid (Size)$0.41 (50)
Ask (Size)$0.42 (120)
Day Low / High$0.38 - 0.43
Volume1.2 M
  • Latest Stories
  • Commentary and Analysis
--HC Wainwright Lowers Trevena's Price Target to $3.50 From $5, Maintains Buy Rating
1:08PM ET 5/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (TRVN) TREVENA Posts Q1 Revenue $20,000, vs. Street Est of $0.352M
7:00AM ET 5/11/2022 MT Newswires


Trevena Says Study on Pain Management Drug Olinvyk Shows Reduced Impact on Respiratory Function on Elderly
8:29AM ET 4/20/2022 MT Newswires

Trevena (TRVN) said Wednesday that a study on Olinvyk, which is intended for the management of acute pain, showed a statistically significant reduced...

Trevena Secures First $15 Million Tranche from Royalty-Based Financing with R-Bridge Healthcare Fund
7:11AM ET 4/18/2022 MT Newswires

Trevena (TRVN) said Monday that it has secured the first $15 million tranche from its royalty-based financing agreement with an affiliate of R-Bridge...

Trevena Obtains Financing of Up to $40 Million From R-Bridge Healthcare Fund
7:58AM ET 3/31/2022 MT Newswires

Trevena (TRVN) said Thursday it has obtained a royalty-based financing of up to $40 million from R-Bridge Healthcare Fund. The biopharmaceutical company...

Trevena Seeks Chinese Approval for Acute Pain Management Injection
11:51AM ET 1/27/2022 MT Newswires

Trevena (TRVN) said Thursday that partner Jiangsu Nhwa Pharmaceutical has filed a new drug application with China's National Medical Products...

Trevena to Advance TRV045 Into Early Stage Trial for Diabetic Neuropathic Pain
9:19AM ET 12/13/2021 MT Newswires

Trevena (TRVN) said Monday it will advance TRV045 into an early stage trial for the potential treatment of diabetic neuropathic pain, a complication of...

-- Earnings Flash (TRVN) TREVENA Reports Q3 Revenue $181,000, vs. Street Est of $0.706M
7:06AM ET 11/15/2021 MT Newswires


Trevena's COVID-19 Drug Well-Tolerated, Potentially Beneficial to Patients in Proof-of-Concept Study
7:51AM ET 9/30/2021 MT Newswires

Trevena (TRVN) said Thursday data from its proof-of-concept study of TRV027 for treating hospitalized COVID-19 patients showed the drug was well-tolerated...

Wake Forest Baptist Health Joins Trevena's Olinvyk Study; Shares Rise Midday
12:57PM ET 8/25/2021 MT Newswires

Trevena (TRVN) reported that the Wake Forest Baptist Health Medical Center will join a study that is examining the impact of Olinvyk injection on...